Molecular diagnostic developer Immunexpress has secured $6m in financing led by Switzerland's Debiopharm Group, to advance development of its SeptiCyte technology and to bring one of its late-stage sepsis diagnostic products to market.
The SeptiCyte technology quantifies multiple specific host response molecular markers from a patient’s immune system for early diagnosis, detection, triage, screening, and severity assessment.
Results from Immunexpress clinical trials show that biomarkers of the patient’s immune response are more accurate and instructive than pathogen detection for the early detection and management of sepsis. The SeptiCyte technology is the basis for a range of investigational products in the Immunexpress pipeline.
Since June 2012, Debiopharm and Immunexpress have been collaborating on the development of one of the Immunexpress investigational products for triaging patients in Emergency Rooms.
Immunexpress president and CEO Dr Roslyn Brandon said this is an important milestone for Immunexpress and, ultimately, for the health care community worldwide which is in need of new, improved methods to more quickly and accurately identify and diagnose patients suspected of sepsis.
"Support and funding from Debiopharm will provide us with the resources necessary to advance and commercialize our proprietary SeptiCyte technology for critical care patients," Dr Brandon added.